China Sky One Medical Obtains SFDA Approval for Ciclopirox Olamine Vaginal Suppositories

July 23, 2010

HARBIN, China, July 23 /PRNewswire-Asia-FirstCall/ — China Sky One
Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company in the People’s Republic of
(“PRC”), today announced that the Company has obtained approval from the
State Food and Drug Administration (SFDA) in China for the production of
Ciclopirox Olamine Vaginal Suppositories. The document number for this drug is

Ciclopirox Olamine Vaginal Suppositories were developed by CSKI’s internal
R&D team based on registration standards of similar imported drugs. The drug’s
main ingredient, Ciclopirox Olamine, is a synthetic broad-spectrum
antibacterial that has been proven effective in clinical studies for treatment
of fungal vaginal infections (candida albicans vaginitis) and fungal vaginal
inflammation (colpits mycotica). It can resist or restrain most pathogenic
streptomyces, including skin fungus and candida albicans as well as many kinds
of nonpathogenic streptomyces, gram negative bacilli and gram positive bacilli.
The drug is a good treatment option for partial infection as it is minimally
absorbed by the skin.

“We greatly appreciate the dedicated efforts of our R&D and sales teams to
bring new drugs like Ciclopirox Olamine Vaginal Suppositories to market,” said
Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. “We expect to
launch this product in early 2011 and plan on gaining share in this large
market by leveraging our extensive distribution network and strong OTC
pharmaceutical sales force.”

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
(“TDR”), Harbin First Bio-Engineering Company Limited (“First”), Heilongjiang
Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang
Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue
source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as “believe,” “expect,” “may,” “will,”
“should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
the progress of new product development. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in The People’s Republic of China,
variations in cash flow, reliance on collaborative retail partners and on new
product development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or undetected
flaws and defects in products, and other risk factors detailed in reports
filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Yan-qing Liu, CEO
     Email: ir@cski.com.cn

    Investor Relations Contact:
    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353
     Email: mabel.zhang@ccgir.com

SOURCE China Sky One Medical, Inc.

Source: newswire

comments powered by Disqus